In the field of stroke, there is a huge and far from unmet medical need in China. A large number of companies are looking to meet the growing demand in the domestic market. These include internationally recognized companies such as Medtronic (MDT.NYSE), Stryker (SYK.NYSE), and Penumbra, as well as already-listed domestic firms such as Wicresoft Medical (00853.HK) and Pegasus Medical (09996.HK), as well as growing startups such as HealthSize Medical and WoW Bio. Successful ones among them have both the chance to save tens of thousands of stroke patients and the ability to realize commercial success for their companies.
Currently, Chinese companies such as Pejia Medical and Fitness Medical are both latecomers and catching up on this track. In China's neurointerventional device space, companies like Medtronic and Stryker take nearly 90% of the domestic market share.